Safety and effectiveness of vaccines against COVID-19 in children aged 5–11 years: a systematic review and meta-analysis

The Lancet Child & Adolescent Health, Journal Year: 2023, Volume and Issue: 7(6), P. 379 - 391

Published: April 18, 2023

Language: Английский

---

Key Considerations during the Transition from the Acute Phase of the COVID-19 Pandemic: A Narrative Review

Vaccines, Journal Year: 2023, Volume and Issue: 11(9), P. 1502 - 1502

Published: Sept. 19, 2023

The COVID-19 pandemic has been met with an unprecedented response from the scientific community, leading to development, investigation, and authorization of vaccines antivirals, ultimately reducing impact SARS-CoV-2 on global public health. However, is far being eradicated, continues evolve, causes substantial health economic burdens. In this narrative review, we posit essential points its responsible management during transition acute phase pandemic. As discussed, despite Omicron (sub)variant(s) causing clinically milder infections, a negligible pathogen. It requires continued genomic surveillance, particularly if one considers that future (sub)lineages do not necessarily have be milder. Antivirals remain elements in management. former could benefit further development improvements dosing, while seasonal administration latter simplification increase interest tackle vaccine hesitancy. also ensure accessibility pharmaceuticals low-income countries improve understanding their use context long-term goals Regardless location, primary role awareness education must played by healthcare workers, who directly communicate patients serve as models for healthy behaviors.

Language: Английский

---

Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022

International Journal of Infectious Diseases, Journal Year: 2023, Volume and Issue: 130, P. 182 - 188

Published: March 7, 2023

We estimated the BNT162b2 vaccine effectiveness (VE) against any (symptomatic or not) SARS-CoV-2 Delta and Omicron infection among adolescents (aged 12-17 years) in Norway from August 2021 to January 2022.We used Cox proportional hazard models, where status was included as a time-varying covariate models were adjusted for age, sex, comorbidities, residence county, birth country, living conditions.The VE peaked at 68% (95% confidence interval [CI]: 64-71%) 62% CI: 57-66%) days 21-48 after first dose those aged 12-15 years 16-17 years, respectively. Among who received two doses, 93% 90-95%) 35-62 decreased 84% 76-89%) ≥63 vaccination. did not observe protective effect receiving one dose. 53% 43-62%) 7-34 second 23% 3-40%) vaccination.We found reduced protection doses compared Delta. Effectiveness with time vaccination both variants. The impact of on reducing thus transmission is limited during dominance.

Language: Английский

---

Key Essentials during the Transition from the Acute Phase of the COVID-19 Pandemic

Published: Aug. 17, 2023

The COVID-19 pandemic has been met with an unprecedented response from the scientific community leading to development, study, and authorization of vaccines antivirals, ultimately reducing impact SARS-CoV-2 on global public health. However, is far being eradicated, continues evolve, causes substantial health economic burdens. In this paper, we posit essential points its management during transition acute phase pandemic. As discussed, despite Omicron (sub)variant(s) causing clinically milder infections, a negligible pathogen. It requires continued genomic surveillance, particularly if one considers that future (sub)lineages do not necessarily have be milder. Antivirals remain elements in management. former could benefit further development improvements dosing, while seasonal administration latter simplification increase interest tackle vaccine hesitancy. also ensure accessibility pharmaceuticals low-income countries improve understanding their use context long-term goals Regardless location, primary role awareness education must played by healthcare workers who directly communicate patients serve as models for healthy behaviors.

Language: Английский

---

Real-world effectiveness of the heterologous SOBERANA-02 and SOBERANA-Plus vaccine scheme in 2–11 years-old children during the SARS-CoV-2 Omicron wave in Cuba: a longitudinal case-population study

The Lancet Regional Health - Americas, Journal Year: 2024, Volume and Issue: 34, P. 100750 - 100750

Published: April 23, 2024

Increased pediatric COVID-19 occurrence due to the SARS-CoV-2 Omicron variant has raised concerns about effectiveness of existing vaccines. The protection provided by SOBERANA-02-Plus vaccination scheme against this not yet been studied. We aimed evaluate scheme's symptomatic infection and severe disease in children.

Language: Английский

---

Navigating the shots: Parental willingness to immunize their children with COVID-19 vaccines in Saudi Arabia explored through a systematic review and meta-analysis

PLoS ONE, Journal Year: 2025, Volume and Issue: 20(1), P. e0317983 - e0317983

Published: Jan. 27, 2025

Introduction Although COVID-19 vaccines have been recommended for children and adolescents since 2021, suboptimal vaccination uptake has documented. No previous systematic review/meta-analysis (SRMA) investigated parents’ willingness to administer their in Saudi Arabia. Accordingly, this SRMA aimed estimate immunize with Arabia identify reasons determinants influencing decisions. Methods This adhered the PRISMA guidelines protocol was registered on PROSPERO (ID: CRD42023492760). An extensive search performed across electronic databases including Pub Med, Med Central, ISI Web of science, Science Core Collection, Medline, KCI-Korean Journal Database, ProQuest, SciELO, relevant studies published from January 1, 2020 October 30, 2023. A random-effects model utilized pooled effects considering expected variability studies. Heterogeneity, risk bias, publication bias quality were considered evaluated by appropriate tests ensure robust results. Results Twenty-five 30,844 parents included. The overall rate who intended 48.0% (95% CI: 41.0–54.0%) high heterogeneity ( I 2 = 99.42%). main reason vaccinate protect child, family community COVID-19. Perceived efficacy/safety most significant associated children. Conclusion first which emphasized priority focus vaccine-related factors as main/key strategy vaccines’ drivers convince a logical way based accurate cumulative emerging scientific data about efficacy safety optimize children/adolescents. can provide valuable insights development evidence-based policies improve parental children, is crucial controlling SARS-CoV-2 spread promoting herd immunity particularly if virus continues pose major threat.

Language: Английский

---

Estimating COVID-19 vaccine effectiveness among children and adolescents using data from a school-based weekly COVID-19 testing program

Vaccine, Journal Year: 2025, Volume and Issue: 61, P. 127292 - 127292

Published: May 31, 2025

Language: Английский

---

Effectiveness of COVID-19 vaccines among children 6–11 years against hospitalization during Omicron predominance in Malaysia

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: March 8, 2024

Abstract There is currently limited data on the effectiveness of COVID-19 vaccines for children aged 6–11 years in Malaysia. This study aims to determine vaccine (VE) against COVID-19-related hospitalization after receipt one- and two-doses BNT162b2 mRNA (Comirnaty-Pfizer/BioNTech) over a duration almost 1 year predominantly Omicron period BA.4/BA.5 X.B.B sub lineages. linked administrative databases between May 2022 March 2023 evaluate real-world pre-dominant with During Omicron-predominant period, cumulative rate was two times higher unvaccinated (9.6 per million population) compared vaccinated (6 population). The estimated VE one dose 27% (95% CI − 1%, 47%) 38% 27%, 48%) doses. remained stable when stratified by time. first 90 days be 45% 33, 55%), followed 47% 34, 56%) 180 days, 36% 22, 45%) 360 days. Recent infection within 6 months does not appear modify impact vaccination risk hospitalization, subject caveat potential underestimation. In our pediatric population, provided moderate-non-diminishing protection predominance.

Language: Английский

---

Booster Vaccination with BNT162b2 Improves Cellular and Humoral Immune Response in the Pediatric Population Immunized with CoronaVac

Published: Feb. 9, 2024

The SARS-CoV-2 Omicron variant and its sublineages continue to cause COVID-19—associated pediatric hospitalizations, severe disease, death globally. BNT162b2 CoronaVac are among the top most widely used COVID-19 vaccines. Much less is known on Wuhan-Hu-1 strain based vaccines in population compared adults. Given worldwide need for booster vaccinations stimulate immune response against new variants of SARS-CoV-2, we characterized humoral cellular BA.1 a aged 10 16 years who received heterologous vaccination two doses CoronaVac, (2x) plus one [CoronaVac(2x) + (1x)], (2x)], three BNT162b2. We observed that (2x)] showed higher anti-S1 neutralizing antibody titers CD4 CD8 T cell immunity specific immunization with alone. Furthermore, from all groups tested, was highest individuals conclude promotes greater

Language: Английский

---

Worldwide SARS-CoV-2 Omicron variant infection: Emerging sub-variants and future vaccination perspectives

Journal of the Formosan Medical Association, Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 1, 2024

The coronavirus disease 2019 (COVID-19) pandemic has sparked widespread concern globally, particularly with the Omicron variant and its sub-lineages emerging as predominant cause of infection for nearly two years. Taiwan's successful containment COVID-19, underscored by broad vaccine coverage, utilization anti-viral therapeutics, timely response strategies, resulted in reduced excess mortality. Moreover, there is a crucial need phased exit strategy, balancing efforts to curtail transmission mitigation socioeconomic impacts from rigorous measures. In this review, we examined evolution epidemiological landscape severe acute respiratory syndrome 2 (SARS-CoV-2) sub-variants Taiwan well other countries world. We also critically evaluated effectiveness COVID-19 vaccines against various SARS-CoV-2 variants. Additionally, addressed advantages heterologous immunization fluctuations neutralizing antibody titers, complexities establishing protective correlates among swiftly mutating viral

Language: Английский

---